Cargando…

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?

Detalles Bibliográficos
Autores principales:	Kreuter, Michael, Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836216/ https://www.ncbi.nlm.nih.gov/pubmed/35148483 http://dx.doi.org/10.1164/rccm.202201-0049ED

Ejemplares similares

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Interstitial lung abnormalities: do symptoms matter?
por: Patel, Avignat S.
Publicado: (2023)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2018)

Interstitial lung disease:  course report
por: Kreuter, Michael, et al.
Publicado: (2020)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2016)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2019)

Interstitial Lung Abnormalities: An Evolving Entity
por: Tomassetti, Sara, et al.
Publicado: (2022)

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Interstitial Lung Abnormalities and Aging Biomarkers: A Mediation
por: Oldham, Justin M.
Publicado: (2021)

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited
por: Walsh, Simon L. F., et al.
Publicado: (2019)

Pinocchio, Interstitial Lung Abnormalities, and Becoming a Real Disease
por: Putman, Rachel K., et al.
Publicado: (2023)

Adult Interstitial Lung Abnormalities: The New Frontier of Pulmonary Fibrosis
por: Luo, FengMing, et al.
Publicado: (2023)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Treating lung cancer in patients with interstitial lung disease: what do we know?
por: Graur, Alexander, et al.
Publicado: (2023)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

The Promise of Quantitative Computed Tomographic Analysis in Assessing Progression of Interstitial Lung Abnormalities and Emphysema in Smokers
por: Larici, Anna Rita, et al.
Publicado: (2023)

Do Circulating Monocytes Promote and Predict Idiopathic Pulmonary Fibrosis Progression?
por: Fernandez, Isis E., et al.
Publicado: (2021)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease
por: Kreuter, Michael, et al.
Publicado: (2022)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Interstitial lung abnormalities and physical function
por: Axelsson, Gisli Thor, et al.
Publicado: (2018)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Increased monocyte level is a risk factor for radiological progression in patients with early fibrotic interstitial lung abnormality
por: Achaiah, Andrew, et al.
Publicado: (2022)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP)
por: Hino, Takuya, et al.
Publicado: (2021)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

TNF-driven cell fate: till HACE do us part
por: Tortola, Luigi, et al.
Publicado: (2016)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
por: Cottin, Vincent
Publicado: (2019)

Interstitial lung abnormalities: Real‐world evidence
por: Rôlo Silvestre, Carina, et al.
Publicado: (2023)

Incidence and Fate of the Abnormal Septal Motion after Open Heart Surgeries
por: Park, Jae-Hyeong
Publicado: (2014)

Bronchial epithelial gene expression and interstitial lung abnormalities
por: Menon, Aravind A., et al.
Publicado: (2023)

Comorbidities in unclassifiable interstitial lung disease
por: Prior, Thomas Skovhus, et al.
Publicado: (2022)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
por: Zhou, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_apn1sp5s5onjjjnvdfj3h0od48